Jadhav, Bhagwat S. published the artcileSynthesis and In-silico Identification of New Bioactive 1,3,4-oxadiazole Tagged 2,3-dihydroimidazo[1,2-a]pyridine Derivatives, Quality Control of 104-01-8, the main research area is oxadiazolyl imidazopyridine mycobacterium tuberculosis antitumor human mol docking.
A set of five new 1,3,4-oxadiazolyl-imidazo-1,2-pyridine derivatives I (R = Bn, 2-ClC6H4CH2, 4-MeOC6H4, etc.) was synthesized and screened in-vitro for their antibacterial activity against Mycobacterium tuberculosis (H37 RV strain) ATCC No-27294. Results: Compound I (R = 2-ClC6H4CH2) displayed potent antitubercular activity at MIC 6.25μg/mL. In-silico mol. docking studies were performed for the evaluation of the binding patterns of compounds I in the binding site of proteins like, Pantothenate synthatase and enoyl acyl reductase inhibitor. The outcomes of the in-vitro antitubercular studies were in good agreement with the mol. docking studies. These newly synthesized compounds were found to have a good ADMET profile. Authors also explored possible anticancer activity using in-silico methods. These results show that readily synthesized 1,3,4-oxadiazolyl-imidazo-1,2-pyridine derivatives I are attracting a new class of potent anti-TB targets as well as possible anticancer activity that worth addnl. opportunities for improvements.
Current Bioactive Compounds published new progress about Antitumor agents. 104-01-8 belongs to class isoquinoline, name is 4-Methoxyphenylacetic acid, and the molecular formula is C9H10O3, Quality Control of 104-01-8.
Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem